



Investor webinar: Strong US commercial traction, accelerated EchoSolv AS uptake, sales team expansion and near-term opportunities

Sydney: AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise to will host an investor webinar at 11:00am AEST (9:00am AWST) on Thursday, 14 May 2026.

Chief Executive Officer, Mr Dustin Haines and US President and General Manager, Mr Nick Lubbers will provide an overview of the Company’s latest milestones, which include the expansion of Echo IQ’s commercial agreement with the Mayo Clinic for EchoSolv HF, providing a potential distribution pathway across the Mayo Clinic Platform network and more than 80 external partner hospitals following anticipated FDA clearance, the recent deployment of EchoSolv AS within the Mount Sinai Health System, one of the leading cardiovascular healthcare networks in the US. The webinar will also cover the Company’s growing US sales pipeline, as well as other developments including sales team expansion and near-term opportunities.

The briefing will be followed by a Q&A session.

Questions can be submitted prior to investors@echoiq.ai or in written form during the webinar.

Anyone wishing to attend the webinar must register using the below link.

Webinar details:

Date and time: 11:00am AEST (9:00am AWST) on Thursday, 14 May 2026

Register at: https://us02web.zoom.us/webinar/register/WN_nL2a3qYKSCm5zXBtVMFzBw

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdjr.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and for the purposes of ASX Listing Rule 3.1 and ASX Guidance Note 8. Forward-looking statements are statements that are not historical facts and may include, without limitation, statements regarding Echo IQ’s commercial growth strategy, anticipated expansion of EchoSolv AS adoption, development of partnerships with health systems and cardiology practices, expected market adoption of AI-enabled decision support tools, and the potential benefits of EchoSolv AS for clinical decision-making and patient care.

These forward-looking statements reflect the current expectations, assumptions, and beliefs of Echo IQ Limited based on information currently available to the company.

Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such factors include, but are not limited to:

For personal use only



Regulatory Risks: the ability of Echo IQ to maintain FDA 510(k) clearance for EchoSolv AS, obtain or maintain any additional required regulatory approvals in the United States or other jurisdictions, and achieve reimbursement coverage from government and private payors;
Commercial Risks: the rate at which health systems and cardiology practices adopt EchoSolv AS, the ability of the company to execute on existing commercial agreements including with The Mount Sinai Hospital, performance under and renewal of customer contracts, and the competitive environment for AI-enabled medical software;
Financial Risks: the availability of sufficient funding to execute the company's commercial strategy, the timing and magnitude of revenue generation, and the company's ability to achieve and sustain profitability; and
Operational Risks: the performance and reliability of EchoSolv AS technology in real-world clinical environments, the ability to integrate EchoSolv AS into existing clinical workflows, and broader market acceptance of AI-based decision support tools in cardiology.

The assumptions underlying the forward-looking statements in this release are made as of the date of this release and are subject to change without notice. Echo IQ cautions that the foregoing list of risk factors is not exhaustive. Investors and prospective investors should carefully consider these factors, as well as those disclosed in Echo IQ's periodic filings with the ASX and other public disclosures, before making any investment decision.

Echo IQ undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation, including the ASX Listing Rules and the U.S. securities laws.

TM Registered trademark or trademark of Echo IQ Ltd. or its affiliates. © 2025 Echo IQ Ltd. All rights reserved.

For personal use only